Still Too Few Women in Cancer Trials
The News Review:
- Still Too Few Women in Cancer Trials
- Novartis to help educate a new generation of researchers
- intrinsiq Acquires Market Research Firm WWMR
Still Too Few Women in Cancer Trials
Atlanta Journal Constitution
Studies need to be able to assess whether there are differences in responses to treatment” she added. In the report published in the July 15 issue of the journal Cancer the researchers looked at all original clinical cancer research published in 2006 in five major cancer journals (the Journal of Clinical ncology the Journal of the National Cancer Institute The Lancet ncology Clinical Cancer Research and Cancer) and three major general medical journals (the New England Journal of Medicine the Journal of the American Medical Association and The Lancet). The importance of including women in clinical research is stressed in the U. National Institutes of Health’s Revitalization Act of 1993 which states that enrolling adequate numbers of women in clinical trials allows for subgroup analysis. Researchers have often been told to avoid including vulnerable populations in their studies including women of childbearing age. “By protecting them from research we’re excluding them” Jagsi said.
Related from Cnurology: New prostate cancer treatment drawing US patients doctors to Mexico
Novartis to help educate a new generation of researchers
FierceVaccines
Novartis will bring its scientific know-how to the class which will largely be made up of doctors from African and Asian countries. “The best place to develop a vaccine for developing countries is the developing country” Dr. Giovanni Della Cioppa head of Global Clinical Research & Development for Novartis Vaccines tells FierceVaccines. Key factors like engineering a vaccine’s resistance to high temperatures and use of local storage facilities would be built into the research programs pushing the researchers to come up with treatments that are ideal for that environment. And these new experts on vaccine development will be free to work with any developers. “For all of those interested in big-scale clinical research creating new centers of excellence outside of the normal very expensive environment of North America and Europe would be of great interest” says Dr.
intrinsiq Acquires Market Research Firm WWMR
PharmaLive.com (press release)
For the first time primary research panels can be quickly assembled and tightly aligned with IntrinsiQ’s real-time database of more than 600 oncologists nationwide and their practice behavior. Founded 15 years ago WWMR brings deep expertise in oncology research having established and served as the secondary market research arm of Genentech for the past decade. The boutique firm specializes in qualitative and quantitative market research product and market assessments forecasts and economic analysis conducted through every stage of the clinical research and drug development process. “As oncology treatment becomes more complex and more specialized the stakes get raised on pharmaceutical teams’ sizeable R&D investment” said Mike Raquet general manager of IntrinsiQ’s pharmaceutical information division. “WWMR brings deep understanding and immediate access to doctors on the front lines – the best way for pharmaceutical companies to affirm strategic directions sooner and with greater assurances for RI. ”Twenty-seven of the top 30 pharmaceutical oncology organizations rely on IntrinsiQ’s unmatched database of 2 million drug administrations given annually collected from oncology practices nationwide using IntrinsiQ’s flagship clinical oncology software IntelliDose®. “This alignment is a perfect marriage because of our organizations’ shared mission of improving the quality and understanding of cancer care” said Susan lsen WWMR founder and president who becomes vice president consulting services in IntrinsiQ’s pharmaceutical information division.
Written by admin on June 11th, 2009 with
no comments.
Read more articles on News.